The U.S. District Court of Northern Texas ruled to dismiss Humana’s (HUM) lawsuit against the Center for Medicare and Medicaid Services, in line with Mizuho’s expectations. The firm, which has an Outperform rating and $316 price target on Humana shares, believes the loss was expected and that Humana’s argument was too broad-based and lacking pointed evidence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana can refile Stars lawsuit at later date, says Barclays
- Humana falls after failing in bid to reverse cuts to Medicare bonus payment
- Humana loses in suit to reverse Medicare bonus payment cut, Bloomberg reports
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- U.S. Health insurers prescription drug denials on the rise, NYT says